Strategic Partnerships Nonacus has recently partnered with The London Clinic to expand access to its non-invasive GALEAS bladder cancer test within the NHS and private healthcare sectors, presenting opportunities to offer additional diagnostic solutions to leading healthcare providers.

Product Innovation The company continually launches advanced NGS-based panels such as GALEAS HereditaryPlus and GALEAS Tumor, opening avenues to cross-sell complementary genetic testing services to clinicians seeking comprehensive cancer diagnostic tools.

Expanding Service Portfolio With a focus on non-invasive and early detection tests for bladder and hereditary cancers, Nonacus can target urology and oncology clinics that aim to reduce invasive procedures and enhance early diagnosis strategies.

Market Penetration Nonacus’ involvement in high-profile medical conferences and collaborations indicates a focus on increasing visibility among leading healthcare providers, making it a strategic partner for institutions seeking innovative, scalable genetic testing solutions.

Growth Potential Operating in a competitive yet growing sector with a revenue ranging from one to ten million dollars, Nonacus presents opportunities for scaling sales through targeted outreach to hospitals, research labs, and private clinics interested in cutting-edge genomic diagnostics.